Monitor the final pricing and size of the offering once announced. The offering is critical to fund operations and satisfy the Haisco license condition; failure to raise sufficient capital could jeopardize the license. Expect near-term volatility as the market prices the dilutive impact.
Price Chart
Executive Summary
Nuvectis Pharma filed a preliminary prospectus supplement for an underwritten public offering of common stock. The offering size, price, and net proceeds are not yet disclosed, but proceeds are intended to fund pipeline development and satisfy a $50 million financing condition in the recently signed Haisco license agreement. The company had only $25.1 million in cash as of March 31, 2026, and an accumulated deficit of $105.7 million, making this dilutive offering a material event for a pre-revenue clinical-stage biotech.
Key Facts
- Preliminary prospectus supplement for an underwritten common stock offering; terms (shares, price, net proceeds) are not yet set.
- Company had $25.1 million in cash and $105.7 million accumulated deficit as of March 31, 2026.
- Recent Haisco license agreement (June 22, 2026) requires the company to raise $50 million within six months or the license may be terminated.
- Stock closed at $27.19 on June 26, 2026, with 26,525,533 shares outstanding.
- Underwriter is Cantor Fitzgerald; commission is 6.0% of gross proceeds; 45-day lock-up for company and insiders.
Financial Impact
Undisclosed amount; proceeds will be used to advance NXP100, NXP200, NXP900 programs and satisfy Haisco financing condition. Dilution will be significant relative to current 26.5M shares outstanding.
Risk Factors
- Significant dilution to existing shareholders from the offering.
- Inability to raise the required $50 million could lead to termination of the Haisco license.
- Pre-revenue clinical-stage company with high cash burn and no approved products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-078864 |
| Document: 0001104659-26-078864-index-headers.html | 0001104659-26-078864 |
| Document: 0001104659-26-078864-index.html | 0001104659-26-078864 |
| Document: 0001104659-26-078864.txt | 0001104659-26-078864 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 11w ago | 8-K | $20.10 $23.06 | ▲ +14.73% | ▲ +15.96% | $18.49 (−8.01%) |
Jul 1, 2026 16w ago | Insider Cluster | $19.52 $20.69 | ▲ +5.99% | ▲ +8.18% | $18.49 (−5.28%) |
Jun 30, 2026 16w ago | 8-K | $19.52 $20.69 | ▼ −5.99% | ▼ −8.18% | $18.49 (+5.28%) |
Jun 30, 2026 16w ago | 424B5 | $19.52 $20.69 | ▼ −5.99% | ▼ −8.18% | $18.49 (+5.28%) |
Jun 29, 2026 17w ago | Press Release | $18.39 $19.54 | ▼ −6.25% | ▼ −7.28% | $18.49 (−0.54%) |
Jun 29, 2026 17w ago | 424B5 | $18.39 $19.54 | ▼ −6.25% | ▼ −7.28% | $18.49 (−0.54%) |
Jun 29, 2026 17w ago | 8-K | $18.39 $19.54 | ▲ +6.25% | ▲ +7.28% | $18.49 (+0.54%) |
May 5, 2026 25w ago | 8-K | $9.71 $9.51 | ▼ −2.06% | ▼ −7.01% | $18.49 (+90.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers